Novartis spies new potential for Xolair with CSU filings
This article was originally published in Scrip
Novartis is hoping to carve out another niche for its anti-IGE monoclonal antibody product for moderate to severe asthma, Xolair (omalizumab), this time in chronic spontaneous urticaria (CSU, also known as chronic idiopathic urticaria).
You may also be interested in...
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.
Another failed study in Duchenne muscular dystrophy spells the end for edasalonexent and possibly the firm.
Phase II results look good for one of the first-in-class product’s potential indications, C3 glomerulopathy. The product was highlighted late last year as an up-and-coming pipeline asset.